特发性炎性肌病完全临床应答相关因素的单中心真实世界研究

doi:10.19723/j.issn.1671-167X.2024.02.013

摘要/Abstract

摘要：

目的: 探究影响特发性炎性肌病(idiopathic inflammatory myopathies，IIMs)患者对常规治疗完全临床应答的相关因素。方法: 纳入2000年1月至2023年6月于北京大学人民医院就诊的IIMs患者，通过分析患者的临床特征、实验室检查、免疫学指标和治疗用药，明确影响患者对常规治疗完全临床应答的相关因素。结果: 共纳入635例IIMs患者，其中518例患者完成随访，平均随访时间36.8个月，总体完全临床应答率为50.0%(259/518)。各临床亚型中，皮肌炎(dermatomyositis，DM)、抗合成酶综合征(anti-synthetase syndrome，ASS)和免疫介导坏死性肌病(immune-mediated necrotizing myopathy，IMNM)的完全临床应答率分别为53.5%、48.9%和39.0%。未完全临床应答组与完全临床应答组相比，在临床特征方面，发热(P=0.002)和快速进展型间质性肺病(rapid progressive interstitial lung disease，RP-ILD)(P=0.014)的发生率较高；在实验室检查方面，谷草转氨酶、乳酸脱氢酶、D-二聚体、红细胞沉降率、C反应蛋白和血清铁蛋白水平较高；在治疗用药方面，激素和静脉注射免疫球蛋白(intravenous immunoglobin，IVIG)的使用比例均较高。IMNM(P=0.007)、间质性肺病(P=0.001)、谷草转氨酶高(P=0.012)、血清铁蛋白高(P=0.016)和外周血CD4⁺T细胞计数低(P=0.004)是IIMs未完全临床应答的危险因素。结论: IIMs患者的总体完全临床应答率低，IMNM亚型最低; 起病时存在间质性肺病、谷草转氨酶高、血清铁蛋白高或外周血CD4⁺T细胞计数低的患者应给予积极治疗。

关键词: 特发性炎性肌病, 临床应答, 间质性肺病, 危险因素, 自身抗体

Abstract:

Objective: To investigate the correlation factors of complete clinical response in idiopathic inflammatory myopathies (IIMs) patients receiving conventional treatment. Methods: Patients diagnosed with IIMs hospitalized in Peking University People's Hospital from January 2000 to June 2023 were included. The correlation factors of complete clinical response to conventional treatment were identified by analyzing the clinical characteristics, laboratory features, peripheral blood lymphocytes, immunological indicators, and therapeutic drugs. Results: Among the 635 patients included, 518 patients finished the follow-up, with an average time of 36.8 months. The total complete clinical response rate of IIMs was 50.0% (259/518). The complete clinical response rate of dermatomyositis (DM), anti-synthetase syndrome (ASS) and immune-mediated necrotizing myopathy (IMNM) were 53.5%, 48.9% and 39.0%, respectively. Fever (P=0.002) and rapid progressive interstitial lung disease (RP-ILD) (P=0.014) were observed much more frequently in non-complete clinical response group than in complete clinical response group. The aspartate transaminase (AST), lactate dehydrogenase (LDH), D-dimer, erythrocyte sedimentation rate (ESR), C-reaction protein (CRP) and serum ferritin were significantly higher in non-complete clinical response group as compared with complete clinical response group. As for the treatment, the percentage of glucocorticoid received and intravenous immunoglobin (IVIG) were significantly higher in non-complete clinical response group than in complete clinical response group. Risk factor analysis showed that IMNM subtype (P=0.007), interstitial lung disease (ILD) (P=0.001), eleva-ted AST (P=0.012), elevated serum ferritin (P=0.016) and decreased count of CD4⁺T cells in peripheral blood (P=0.004) might be the risk factors for IIMs non-complete clinical response. Conclusion: The total complete clinical response rate of IIMs is low, especially for IMNM subtype. More effective intervention should be administered to patients with ILD, elevated AST, elevated serum ferritin or decreased count of CD4⁺T cells at disease onset.

Key words: Idiopathic inflammatory myopathies, Clinical response, Interstitial lung disease, Risk factors, Autoantibodies

中图分类号:

R593.26

赖展鸿,李嘉辰,贠泽霖,张永刚,张昊,邢晓燕,邵苗,金月波,王乃迪,李依敏,李玉慧,栗占国. 特发性炎性肌病完全临床应答相关因素的单中心真实世界研究[J]. 北京大学学报（医学版）, 2024, 56(2): 284-292.

Zhanhong LAI,Jiachen LI,Zelin YUN,Yonggang ZHANG,Hao ZHANG,Xiaoyan XING,Miao SHAO,Yuebo JIN,Naidi WANG,Yimin LI,Yuhui LI,Zhanguo LI. A unicenter real-world study of the correlation factors for complete clinical response in idiopathic inflammatory myopathies[J]. Journal of Peking University (Health Sciences), 2024, 56(2): 284-292.

图/表 7

图1

表1

图2

表2

图3

表3

图4

参考文献 45

1	Tanboon J , Nishino I . Classification of idiopathic inflammatory myopathies: Pathology perspectives[J]. Curr Opin Neurol, 2019, 32 (5): 704- 714. doi: 10.1097/WCO.0000000000000740
2	DeWane ME , Waldman R , Lu J . Dermatomyositis: Clinical features and pathogenesis[J]. J Am Acad Dermatol, 2020, 82 (2): 267- 281. doi: 10.1016/j.jaad.2019.06.1309
3	罗澜, 邢晓燕, 肖云抒, 等. 抗合成酶综合征合并心脏受累患者的临床及免疫学特征[J]. 北京大学学报(医学版), 2021, 53 (6): 1078- 1082.
4	Marco JL , Collins BF . Clinical manifestations and treatment of antisynthetase syndrome[J]. Best Pract Res Clin Rheumatol, 2020, 34 (4): 101503. doi: 10.1016/j.berh.2020.101503
5	Pinal-Fernandez I , Casal-Dominguez M , Mammen AL . Immune-mediated necrotizing myopathy[J]. Curr Rheumatol Rep, 2018, 20 (4): 21. doi: 10.1007/s11926-018-0732-6
6	Wolstencroft PW , Chung L , Li S , et al. Factors associated with clinical remission of skin disease in dermatomyositis[J]. JAMA Dermatol, 2018, 154 (1): 44- 51. doi: 10.1001/jamadermatol.2017.3758
7	Lundberg IE , Fujimoto M , Vencovsky J , et al. Idiopathic inflammatory myopathies[J]. Nat Rev Dis Primers, 2021, 7 (1): 86. doi: 10.1038/s41572-021-00321-x
8	Bohan A , Peter JB . Polymyositis and dermatomyositis (first of two parts)[J]. N Engl J Med, 1975, 292 (7): 344- 347. doi: 10.1056/NEJM197502132920706
9	Bohan A , Peter JB . Polymyositis and dermatomyositis (second of two parts)[J]. N Engl J Med, 1975, 292 (8): 403- 407. doi: 10.1056/NEJM197502202920807
10	Lundberg IE , Tjärnlund A , Bottai M , et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups[J]. Arthritis Rheumatol, 2017, 69 (12): 2271- 2282. doi: 10.1002/art.40320
11	Allenbach Y , Mammen AL , Benveniste O , et al. 224th ENMC International Workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016[J]. Neuromuscul Disord, 2018, 28 (1): 87- 99. doi: 10.1016/j.nmd.2017.09.016
12	Oddis CV , Rider LG , Reed AM , et al. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies[J]. Arthritis Rheum, 2005, 52 (9): 2607- 2615. doi: 10.1002/art.21291
13	Aggarwal R , Rider LG , Ruperto N , et al. 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative[J]. Ann Rheum Dis, 2017, 76 (5): 792- 801. doi: 10.1136/annrheumdis-2017-211400
14	Tiniakou E , Mecoli CA , Kelly W , et al. Anti-MDA5-positive dermatomyositis and remission in a single referral centre population[J]. Clin Exp Rheumatol, 2023, 41 (2): 309- 315.
15	Rider LG , Werth VP , Huber AM , et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and patient/parent global activity, manual muscle testing (MMT), health assessment questionnaire (HAQ)/childhood health assessment questionnaire (C-HAQ), childhood myositis assessment scale (CMAS), myositis disease activity assessment tool (MDAAT), disease activity score (DAS), short form 36 (SF-36), child health questionnaire (CHQ), physician global damage, myositis damage index (MDI), quantitative muscle testing (QMT), myositis functional index-2 (FI-2), myositis activities profile (MAP), inclusion body myositis functional rating scale (IBMFRS), cutaneous dermatomyositis disease area and severity index (CDASI), cutaneous assessment tool (CAT), dermatomyositis skin severity index (DSSI), skindex, and dermatology life quality index (DLQI)[J]. Arthritis Care Res (Hoboken), 2011, 63 (Suppl 11): S118- S157.
16	Li Y , Li Y , Wu J , et al. Predictors of Poor Outcome of Anti-MDA5-associated rapidly progressive interstitial lung disease in a Chinese cohort with dermatomyositis[J]. J Immunol Res, 2020, 2020, 2024869.
17	Sultan SM , Ioannou Y , Moss K , et al. Outcome in patients with idiopathic inflammatory myositis: Morbidity and mortality[J]. Rheumatology (Oxford), 2002, 41 (1): 22- 26. doi: 10.1093/rheumatology/41.1.22
18	Lee JS , Lee JE , Hong S , et al. Prognostic factors for steroid-free remission in patients with idiopathic inflammatory myopathies: Importance of anthropometric measurements[J]. Ther Adv Musculoskelet Dis, 2020, 12, 1759720x20936822.
19	Watanabe E , Gono T , Kuwana M , et al. Predictive factors for sustained remission with stratification by myositis-specific autoantibodies in adult polymyositis/dermatomyositis[J]. Rheumatology (Oxford), 2020, 59 (3): 586- 593.
20	Mariampillai K , Granger B , Amelin D , et al. Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoanti-bodies[J]. JAMA Neurol, 2018, 75 (12): 1528- 1537. doi: 10.1001/jamaneurol.2018.2598
21	Watanabe Y , Uruha A , Suzuki S , et al. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy[J]. J Neurol Neurosurg Psychiatry, 2016, 87 (10): 1038- 1044. doi: 10.1136/jnnp-2016-313166
22	Merlonghi G , Antonini G , Garibaldi M . Immune-mediated necrotizing myopathy (IMNM): A myopathological challenge[J]. Autoimmun Rev, 2022, 21 (2): 102993. doi: 10.1016/j.autrev.2021.102993
23	杨红霞, 田小兰, 江薇, 等. 免疫介导坏死性肌病的临床和病理特征分析[J]. 北京大学学报(医学版), 2019, 51 (6): 989- 995.
24	Tiniakou E , Pinal-Fernandez I , Lloyd TE , et al. More severe disease and slower recovery in younger patients with anti-3-hydro-xy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy[J]. Rheumatology (Oxford), 2017, 56 (5): 787- 794.
25	Day JA , Limaye V . Immune-mediated necrotising myopathy: A critical review of current concepts[J]. Semin Arthritis Rheum, 2019, 49 (3): 420- 429. doi: 10.1016/j.semarthrit.2019.04.002
26	Redondo-Benito A , Curran A , Villar-Gomez A , et al. Opportunistic infections in patients with idiopathic inflammatory myopathies[J]. Int J Rheum Dis, 2018, 21 (2): 487- 496. doi: 10.1111/1756-185X.13255
27	Sun S , Chen Z , Zhang D , et al. Description and analysis of a novel subtype of the anti-synthetase syndrome characterized by frequent attacks of fever and systemic inflammation in a single-center cohort study[J]. Front Immunol, 2021, 12, 729602. doi: 10.3389/fimmu.2021.729602
28	Debray MP , Borie R , Revel MP , et al. Interstitial lung disease in anti-synthetase syndrome: Initial and follow-up CT findings[J]. Eur J Radiol, 2015, 84 (3): 516- 523. doi: 10.1016/j.ejrad.2014.11.026
29	Hallowell RW , Ascherman DP , Danoff SK . Pulmonary manifestations of polymyositis/dermatomyositis[J]. Semin Respir Crit Care Med, 2014, 35 (2): 239- 248. doi: 10.1055/s-0034-1371528
30	李玉慧, 姚海红, 张学武, 等. 94例皮肌炎患者器官受累及免疫学特征分析[J]. 北京大学学报(医学版), 2010, 42 (2): 140- 142. doi: 10.3969/j.issn.1671-167X.2010.02.005
31	Johnson C , Pinal-Fernandez I , Parikh R , et al. Assessment of mortality in autoimmune myositis with and without associated interstitial lung disease[J]. Lung, 2016, 194 (5): 733- 737. doi: 10.1007/s00408-016-9896-x
32	Chen IJ , Wu YJJ , Lin CW , et al. Interstitial lung disease in polymyositis and dermatomyositis[J]. Clin Rheumatol, 2009, 28 (6): 639- 646. doi: 10.1007/s10067-009-1110-6
33	Hallowell RW , Danoff SK . Diagnosis and management of myositis-associated lung disease[J]. Chest, 2023, 163 (6): 1476- 1491. doi: 10.1016/j.chest.2023.01.031
34	Li L , Wang H , Wang Q , et al. Myositis-specific autoantibodies in dermatomyositis/polymyositis with interstitial lung disease[J]. J Neurol Sci, 2019, 397, 123- 128. doi: 10.1016/j.jns.2018.12.040
35	Srivastava P , Dwivedi S , Misra R . Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis[J]. Rheumatol Int, 2016, 36 (7): 935- 943. doi: 10.1007/s00296-016-3494-3
36	Li Y , Gao X , Li Y , et al. Predictors and mortality of rapidly progressive interstitial lung disease in patients with idiopathic inflammatory myopathy: A series of 474 patients[J]. Front Med (Lausanne), 2020, 7, 363.
37	Jiang W , Shi JL , Yang HX , et al. Long-term outcomes and prognosis factors in patients with idiopathic inflammatory myopathies based on myositis-specific autoantibodies: A single cohort study[J]. Arthritis Care Res (Hoboken), 2023, 75 (5): 1175- 1182. doi: 10.1002/acr.24993
38	Komac A , Gokcen N , Yazici A , et al. The role of lactate dehydrogenase-to-albumin ratio in clinical evaluation of adult-onset Still's disease[J]. Int J Clin Pract, 2021, 75 (10): e14615.
39	Bohan A , Peter JB , Bowman RL , et al. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis[J]. Medicine (Baltimore), 1977, 56 (4): 255- 286. doi: 10.1097/00005792-197707000-00001
40	Tymms KE , Webb J . Dermatopolymyositis and other connective tissue diseases: A review of 105 cases[J]. J Rheumatol, 1985, 12 (6): 1140- 1148.
41	Niu Q , Zhao LQ , Ma WL , et al. A new predictive model for the prognosis of MDA5(+) DM-ILD[J]. Front Med (Lausanne), 2022, 9, 908365.
42	Ding Y , Ge Y . Anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis complicated with macrophage activation syndrome[J]. Ther Adv Chronic Dis, 2022, 13, 20406223221098128.
43	Chen F , Wang D , Shu X , et al. Anti-MDA5 antibody is associa-ted with A/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis[J]. Rheumatol Int, 2012, 32 (12): 3909- 3915. doi: 10.1007/s00296-011-2323-y
44	朱冯赟智, 邢晓燕, 汤晓菲, 等. 肌炎合并血栓栓塞患者的临床及免疫学特征[J]. 北京大学学报(医学版), 2020, 52 (6): 995- 1000.
45	Davalos D , Akassoglou K . Fibrinogen as a key regulator of inflammation in disease[J]. Semin Immunopathol, 2012, 34 (1): 43- 62. doi: 10.1007/s00281-011-0290-8

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed

Variables	CCR (n=259)	NCCR (n=259)	P value
Female	195 (75.3)	190 (73.4)	0.615
Age at onset/years	49.3±15.0	50.2±13.6	0.460
DM	146 (56.4)	127 (49.0)	0.095
ASS	60 (23.2)	63 (24.3)	0.757
IMNM	46 (17.8)	72 (27.8)	0.006
Fever	75 (29.0)	109 (42.1)	0.002
Dyspnea	103 (39.8)	91 (35.1)	0.276
Gottron’s sign/papules	158 (61.0)	166 (64.1)	0.468
Mechanic’s hands	72 (27.8)	82 (31.7)	0.336
Heliotrope rash	99 (38.2)	110 (42.5)	0.325
ILD	159 (61.4)	189 (73.0)	0.005
RP-ILD	84 (32.4)	111 (42.9)	0.014
C-ILD	72 (27.8)	67 (25.9)	0.620

Variables	CCR (n=259)	NCCR (n=259)	P value
WBC/(×10⁹/L)	7.53±3.37	7.81±3.66	0.363
Lymphocyte/(×10⁹/L)	1.47±0.84	1.36±0.84	0.146
PLT/(×10⁹/L)	228.0±84.5	223.0±83.1	0.483
ALT/(U/L)	33.0 (20.3, 56.0)	45.5 (20.0, 103.0)	0.509
AST/(U/L)	34.0 (24.2, 69.0)	63.5 (31.0, 132.0)	0.008
LDH/(U/L)	289 (232, 519)	429 (290, 631)	0.001
CK/(U/L)	77.0 (34.5, 251.0)	76.0 (26.8, 775.0)	0.627
D-dimer/(μg/L)	322 (195, 487)	425 (282, 714)	0.002
ESR/(mm/L)	17.5 (8.9, 41.8)	36.5 (12.8, 58.3)	0.003
CRP/(mg/L)	3.43 (0.63, 20.40)	8.03 (2.00, 28.50)	0.002
Ferritin/(μg/L)^a	229 (83, 1 116)	566 (272, 1 588)	0.020
IgG/(g/L)	14.50±6.43	13.90±5.37	0.214
C3/(g/L)	1.00±0.27	1.01±0.27	0.760
C4/(g/L)	0.25±0.12	0.24±0.10	0.575

Variables	CCR (n=259)	NCCR (n=259)	P value
Glucocorticoid, n (%)	206 (79.5)	226 (87.3)	0.018
Prednisone ≤ 15 mg/d^a	63 (24.4)	49 (19.0)	0.135
15 mg/d＜prednisone＜30 mg/d^a	9 (3.5)	9 (3.5)	＞0.999
Prednisone ≥ 30 mg/d^a	119 (46.1)	125 (48.4)	0.597
Pulse IVMP	67 (25.9)	75 (29.0)	0.431
Immunosuppressants, n (%)	166 (64.1)	156 (60.2)	0.365
CTX	96 (37.1)	94 (36.3)	0.855
CSA	54 (20.8)	51 (19.7)	0.743
TAC	10 (3.9)	17 (6.6)	0.166
MMF	20 (7.7)	11 (4.2)	0.095
JAKi, n (%)	2 (0.8)	8 (3.1)	0.055
IVIG, n (%)	25 (9.7)	42 (16.2)	0.026

[1]	朱金荣,赵亚娜,黄巍,赵微微,王悦,王松,苏春燕. 感染新型冠状病毒的血液透析患者的临床特征[J]. 北京大学学报（医学版）, 2024, 56(2): 267-272.
[2]	司筱芊,赵秀娟,朱凤雪,王天兵. 创伤出血性休克后急性呼吸窘迫综合征的危险因素[J]. 北京大学学报（医学版）, 2024, 56(2): 307-312.
[3]	李洋洋,侯林,马紫君,黄山雅美,刘捷,曾超美,秦炯. 孕期因素与婴儿牛奶蛋白过敏的关系[J]. 北京大学学报（医学版）, 2024, 56(1): 144-149.
[4]	刘晓强,周寅. 牙种植同期植骨术围术期高血压的相关危险因素[J]. 北京大学学报（医学版）, 2024, 56(1): 93-98.
[5]	游芳凝,罗靓,刘香君,张学武,李春. 未分化结缔组织病患者的妊娠结局、疾病演变及其影响因素[J]. 北京大学学报（医学版）, 2023, 55(6): 1045-1052.
[6]	罗靓,李云,王红彦,相晓红,赵静,孙峰,张晓盈,贾汝琳,李春. 抗内皮细胞抗体检测在早期流产中的预测价值[J]. 北京大学学报（医学版）, 2023, 55(6): 1039-1044.
[7]	李宇菲,闫亚妮,靳家扬,李春,裴秋艳. 合并胎儿心脏病变的抗SSA抗体阳性孕妇的临床及实验室特征[J]. 北京大学学报（医学版）, 2023, 55(6): 1053-1057.
[8]	孟彦宏,陈怡帆,周培茹. CENP-B抗体阳性的原发性干燥综合征患者的临床和免疫学特征[J]. 北京大学学报（医学版）, 2023, 55(6): 1088-1096.
[9]	魏慧,次旦央宗,益西拉姆,白玛央金. 高原地区不同类型过敏性紫癜藏族患者发病的相关危险因素[J]. 北京大学学报（医学版）, 2023, 55(5): 923-928.
[10]	林咏惟,周雅琳,赵润茏,许雅君,刘燕萍. 孕早期女性铁营养状况及其影响因素分析[J]. 北京大学学报（医学版）, 2023, 55(4): 600-605.
[11]	朱薇,祝斌,刘晓光. 全内镜下突出腰椎间盘摘除术后功能状态的影响因素[J]. 北京大学学报（医学版）, 2023, 55(3): 537-542.
[12]	张琳崎,赵静,王红彦,王宗沂,李英妮,汤稷旸,李思莹,曲进锋,赵明威. 抗ENO1抗体与狼疮性视网膜病变的相关性[J]. 北京大学学报（医学版）, 2022, 54(6): 1099-1105.
[13]	罗靓,蔡青猛,刘香君,贠泽霖,李春,张晓盈. 以雷诺现象为首发表现的系统性硬化症临床特征及其相关因素[J]. 北京大学学报（医学版）, 2022, 54(6): 1224-1228.
[14]	张璐,陈澄,翁梅婷,郑爱萍,苏美玲,王庆文,蔡月明. 狼疮肾炎患者肾小管间质损伤的自身抗体特征[J]. 北京大学学报（医学版）, 2022, 54(6): 1094-1098.
[15]	梁喆,范芳芳,张岩,秦献辉,李建平,霍勇. 中国高血压人群中H型高血压的比率和特征及与美国人群的比较[J]. 北京大学学报（医学版）, 2022, 54(5): 1028-1037.